BACKGROUND: Obesity is characterised by growth hormone (GH) abnormalities, including a blunted response to stimulation and a`paradoxical' increase after meals. The blunted GH release is reversed by a surgical intestinal bypass procedure. However, this does not mean that normal GH dynamics have been restored. The present study assessed whether post-surgical weight reduction in obese patients normalised the modulation of GH release produced by metabolic fuels. SUBJECTS: Ten obese female subjects, aged 23 ± 54 y, were studied before and after biliopancreatic diversion (BPD). All patients, after surgery, had experienced a signi®cant reduction in body weight (mean body mass index (BMI) 25.78 AE 1.01 kgam 2 vs 44.68 AE 1.73 kgam 2 ). Two groups were also studied as controls: Ten normal body weight female subjects and ten patients suffering from anorexia nervosa (AN, mean BMI 17.46 AE 1.12 kgam 2 ). MEASUREMENTS: We have studied the GH response to a GH releasing hormone (GHRH) bolus (1 m mgakg iv, at 13.00 h) before and after a standard meal. RESULTS: In post-BPD subjects, the GH response to GHRH in the fasting state, was clearly augmented in comparison with the pre-BPD values (peak values 18.06 AE 4.56 vs 3.24 AE 0.68 m mgaL). In post-BPD subjects the postprandial GH response was further augmented in comparison with the fasting test (peak 30.12 AE 4.99 m mgaL, P`0.05). This pattern was similar to that observed in anorexic patients. CONCLUSION: The surgical procedure restores a normal GH response to GHRH in the fasting state, but thè paradoxical' GH response after meals remains present, suggesting a persistent GH derangement in such patients, which is not related to body weight per se. The surgical procedure makes obese patients similar to anorexics, in the relationships between metabolic fuels and GH secretion. The persistence of the GH postprandial response to GHRH in post-BPD subjects suggests a role for metabolic fuels in the regulation of somatostatin (SRIF) secretion.
Introduction
It is well known that obese subjects characteristically exhibit a blunted growth hormone (GH) response to both indirect 1,2 and direct 3 stimulation. A partial restoration of GH response after weight loss has been widely described 3 ± 5 and suggests that reduced GH secretion is directly related to body weight (BW) per se or that a common denominator underlies obesity and GH impairment.
There is probably a role for metabolic substrates, since a short-term fast induces an enhancement in GH response, independently from weight reduction. 5 On the other hand, in obesity there also appears to be an abnormal sensitivity of GH secretion to metabolic signals. In a previous paper we showed that in obese subjects a normal meal, at lunch-time, induces à paradoxical' enhancement of GH-releasing hormone (GHRH)-induced GH release; whilst in normal subjects, the GH secretion after the same stimulus is blunted by the meal. 6 The aim of this study was to investigate whether the BW reduction observed in obese subjects after surgical procedure, is able to induce normalisation in GH modulation by metabolic fuels. Therefore, we have evaluated the effects of GHRH administration both before and after meals, in a group of morbidly obese subjects, who, after biliopancreatic diversion (BPD), normalised their BW. We have compared the results with two control groups: normal subjects and anorexia nervosa (AN) patients. The last group was chosen to evaluate the role of macronutrient de®ciencies in the post-surgical subjects; moreover, AN patients exhibited the same`paradoxical' enhancement of GHRHinduced GH release as obese patients, as previously shown. 6 
Subjects and methods
Three groups of subjects were studied, after they had given an informed consent. This study protocol has been approved by the Ethical Committee of our Institution.
The ®rst group consisted of ten morbidly obese patients, who were scheduled to undergo therapeutic BPD 7 (pre-BPD subjects), since dietary therapy had failed for all of them. They were ten females, aged 23±48 y, with a mean body mass index (BMI) of 44.68AE 1.73 kgam 2 (range: 33.70±52.03). They were also studied 16±24 months after having undergone a successful BPD (post-BPD subjects), and their BW had returned partially or completely to normal (mean BMI at the time of testing 25.78AE 1.01 kgam 2 ; range: 20.56±27.72). All patients were studied in a phase of stabilised BW (AE2% variation in BW in the last six months before testing was performed).
The surgical procedure of BPD clearly resembles a Billroth II gastrectomy, with a long Roux-en-Y loop. Cholecystectomy is routinely performed. The size of the gastric pouch is 300±500 ml, thereby ensuring adequate food intake. The bowel length of the alimentary tract is 200 cm and the common tract is 50 cm. As a consequence, food is subtracted to the normal action of biliary and pancreatic secretion except for the common tract. The patients develop fat malabsorption (75% of ingested) and partial starch malabsorption, while maintaining a normal absorption of mono-and disaccharides (19% of ingested starch plus mono-and disaccharides) and normal absorption of proteins. 8 The demonstrated metabolic and hormonal consequences of BPD 9 ± 12 include: 1) reversal of insulin resistance; 2) increased diet-induced thermogenesis; 3) modi®cations of gut hormones, such as gastrin, enteroglucagon, neurotensin, CCK.
The control group consisted of 20 female subjects (10 normal ). The diagnosis of AN was established on the basis of DSM-IV criteria, and, at the time of the tests they had been ill for one to three years. According to DSM-IV criteria, all were affected by restrictive AN. All these patients showed amenorrhea. They were studied in a stabilised phase of their illness, when their BW had been stable in the last month before the tests and they were eating their customary diet (calculated approximately at 900±1000 kcalad). None of them were taking medication which could interfere with pituitary secretion, particularly metoclopramide or antidepressant drugs, for at least two weeks before the tests.
No patients in the other groups were taking medications known to affect GH secretion. Moreover 
Before meal tests
After an overnight fast and having eaten a continental breakfast at 08.00 h, at 12.00 h, a 150 mmolaL NaCl infusion was started, and 1 h later (time zero), a GHRH bolus (1 mgakg of BW, range 35±125 mg i.v.) was injected. Blood samples were collected at 0, 15, 30, 60, 90 min.
After meal tests
On a separate day, after an overnight fast and having eaten a continental breakfast at 08.00 h, the subjects consumed at 12.00 h a 800 kcal meal, composed approximately of 55% carbohydrates, 32% lipids and 13% proteins. At 12.00 h, a 150 mmolaL NaCl infusion was also started, and 1 h later (45 min after ®nishing the meal, time zero), a GHRH bolus (1 mgakg of BW iv) was injected. Blood samples were collected at 0, 15, 30, 60 and 90 min.
The two tests were performed in all subjects, with an interval of at least three days; the sequence of the tests was randomized by use of a random number table. Lunch-time pre-and postprandial GH stimulation test, according to our previous studies, 6, 13 is able to discriminate between patients with nutritional alteration (both AN and obesity) and normal controls.
Post-BPD subjects underwent a second session of tests (both before and after the meal) 16±24 months after surgical procedure.
Basal assays
Plasma insulin, triglycerides, free fatty acids (FFA), HDL-cholesterol, glucose, total proteins, insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) were determined at 08.00 h, after an Plasma GH after biliopancreatic diversion L De Marinis et al overnight fast, on the day during which the ®rst test was performed. GHRH 1-29 was obtained from Serono (Milan, Italy). Plasma GH levels were measured in duplicate by IRMA with reagents purchased by Radim (Pomezia, Italy). The intra-assay coef®cients of variation were 2.5%, 3.4% and 3.9%, respectively, for concentrations of 15.1 AE 0.37 mgaL, 7.9 AE 0.27 mgaL and 3.22 AE 1.14 mgaL, respectively. The inter-assay coef®-cients of variation were 5%, 3.8% and 4.9%, respectively, for concentrations of 3.22AE 0.16 mgaL, 7.80 AE 0.30 mgaL and 14.6AE 0.72 mgaL, respectively. All samples from each individual subject were analysed in duplicate and in the same assay.
Plasma IGF-I was measured by radioimmunoassay (RIA) using kits from Nichols Institute (San Juan Capistrano, CA). Soluble IGF-I was separated from interfering binding proteins by precipitation with ethanol-HCl. IGF-I normal values range from 170± 330 ngaml.
Plasma IGFBP-3 was measured by RIA using commercial kits by Mediagnost (Tu Èbingen, Germany), as previously described by Blum et al.
14 For molar comparison between IGF-I and IGFBP-3 we have considered 30.5 Kda as the molar weight of IGFBP-3, as suggested by Juul et al. Insulin was assayed by RIA using kits from Abbott Diagnostics (Milan, Italy). Intra-assay coef®cients of variation were 1.8% and 4.5%, for concentrations of 203.77 AE 3.66 pmolaL and 431.93AE 17.72 pmolaL, respectively. Inter-assay coef®cients of variation were 6.1% and 5.6%, for concentrations of 200.9AE 12.19 pmolaL and 441.3AE 24.25 pmolaL, respectively. Normal basal plasma insulin levels ranged from 35±145 pmolaL.
Body composition
Total body mass (TBM), lean body mass (LBM) and fat mass (FM) in all subjects, were determined by dual X-ray absorptiometry (DEXA) using a commercial scanner (Lunar DPX, Lunar Europe, Everberg, Belgium).
Statistics
All results are expressed as mean AE standard error of the mean (s.e.m.).
The distribution of the data was tested by the Kolmogorov-Smirnov test to verify whether the samples come from a speci®ed distribution and we found that the data were not normally distributed.
Statistical analysis was performed using the Wilcoxon rank sum test, when comparing before and after meal studies, within the same group of subjects (preor post-BPD, in normal weight controls and in AN patients); and using the Mann-Whitney U-Test when comparing data from different groups. Moreover, GH plasma concentrations were also expressed as area under the curve (AUC) relative to zero, calculated by trapezoidal rule, and compared in the same way. Percentage of GH-AUC variation in after meal tests, with respect to before meal tests, were also calculated.
Stepwise multiple linear regression analysis was used to elucidate the correlation among GH peaks, metabolic parameters and body composition data.
Results

GH response to GHRH
Pre-BPD subjects. The plasma GH responses to GHRH in obese pre-BPD subjects are shown in Figure 1 (left panel) and in Figure 2 . In the before meal study, the GH response was blunted, according to previous studies, 6 with a GH-AUC signi®cantly lower than both normal weight subjects and AN patients ( Figure 2 ). After meal, a signi®cant increase of the GHRH-induced GH release was observed at Figure 1 Mean growth hormone (GH) (AEs.e.m.) response to GH releasing hormone (GHRH) (mg/L) in ten obese pre-biliopancreatic diversion (BPD) subjects (left panel) and in ten post-BPD subjects (right panel). The test was performed in fasting state (dotted line) or after a standard meal (bold line). * P`0.05, ** P`0.02 signi®cance of difference when comparing before and after meal tests in each group.
Plasma GH after biliopancreatic diversion L De Marinis et al 30 min and 60 min (Figure 1 ). The GH-AUC was also signi®cantly augmented after the meal (Figure 2 ). The obese subjects showed an increase in the percentage of variation in GH-AUC after the meal, compared to the before meal test (Figure 3) , which was different from normal weight subjects, who showed a signi®-cant reduction in GH response to GHRH after food intake ( Figure 2 and Figure 3 ).
Post-BPD subjects. In post-BPD subjects, the GH response to GHRH in the before meal study, was signi®cantly greater than in obese pre-BPD (P`0.01) at 15, 30, 60 and 90 min (Figure 1, right panel) . The GH-AUC was markedly augmented in comparison to pre-BPD subjects (Figure 2) . Moreover, GH-AUC in post-BPD patients did not differ from normal weight subjects and the AN group in the fasting study.
After the meal, a clear further increase in GHRHinduced GH release was observed in post-BPD subjects. The GH plasma levels were greater than in the before-meal study at 15, 30, 60 and 90 min (Figure 1,  right panel) . The GH-AUC was also signi®cantly greater than both the before-meal GH-AUC in the same group (Figure 2 ) and the after-meal GH-AUC in the normal weight control group (Figure 2 ) both in absolute terms and when considering the percentage of variation (Figure 3 ). Post-BPD subjects did not differ from AN patients in the after-meal study (Figure 2 and Figure 3 ).
Metabolic parameters
These data are reported in Table 1 . Post-BPD subjects differed from pre-BPD ones in insulin, triglycerides and FFA plasma levels ( 
IGF-I, IGFBP-3, IGF-IaIGFBP3 molar ratio and body composition
These data are reported in Table 2 . Post-BPD patients were different from normal weight subjects when considering IGF-I levels and IGFBP-3 levels, which were signi®cantly lower and IGF-IaIGFBP-3 ratio, which was signi®cantly higher (Table 2, footnote b).
Pre-BPD obese subjects showed signi®cantly lower IGF-I plasma levels than normal weight subjects; Figure 2 Integrated growth hormone-area under the curve (GH-AUC) (mg/L/90 min), before and after meal, in ten pre-biliopancreatic diversion (BPD) obese subjects and in ten post-BPD subjects, in ten normal weight controls and in ten anorexia nervosa (AN) controls. Bars indicate signi®cant differences between groups. Figure 3 Growth hormone-area under the curve (GH-AUC) percent variation in after meal test in comparison with before meal test, in ten obese pre-biliopancreatic diversion (BPD) subjects, in ten post-BPD subjects, in ten normal weight controls and in ten anorexia nervosa (AN) controls.
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however, the reduction in IGFBP-3 was more marked so that IGF-IaIGFBP-3 ratio was signi®cantly higher (Table 2 , footnote a). In AN patients, IGF-I levels were signi®cantly lower than in normal subjects ( Table 2 , footnote d) and obese pre-BPD subjects (Table 2 , footnote e). However, when considering the ratio IGF-IaIGFBP-3, this was signi®cantly lower than in pre-and post-BPD subjects ( Table 2 , footnotes e and f), but was similar to that of normal weight controls. Post-BPD subjects showed TBM and FM signi®-cantly lower than pre-BPD ones ( Table 2 , footnote c).
Multivariate analysis
Multivariate stepwise regression analysis, including insulin, FFA and body composition data, showed a signi®cant correlation between insulin levels and GH peak values both pre-and postprandial (preprandial GH peak 30.3 7 0.06 Âinsulin; r 2 0.33, P 0.002; postprandial GH peak 41.6 7 0.82 Â insulin; r 2 0.31, P 0.004). No signi®cant correlation was observed with FFA levels. Finally, GH peaks correlated with LBM (preprandial GH peak 29.3 7 0.41 ÂFM 7 0.017 LBM; r 2 0.34, P 0.006; postprandial GH peak 47.9 7 0.53 Â FM 7 0.14 LBM; r 2 0.31, P 0.013).
Discussion
According to our previous reports, 6, 16 in this study we have con®rmed the blunted GH response to GHRH in the fasted state in obese pre-BPD subjects and thè paradoxical' response after meals in the same subjects. Different hypotheses have been introduced to explain the blunted GH release in obese subjects. They concern a possible role of both peripheral and central factors.
Among central factors, an augmented somatostatin (SRIF) secretion has been hypothesised. It has been suggested that the defect resides in the pituitary gland, with the enhanced SRIF release being responsible for the blunted GH response. 3 Among peripheral factors, the role of IGF-I has been underlined. The high concentration of plasma IGF-I found in obese Zucker rats could exert a negative feedback on stimulated GH secretion. 17 In our patients, IGF-I was lower than normal subjects, but its bioavailability, 15 measured by IGF-IaIGFBP-3 ratio, seemed to have increased. Another hypothesis concerns the role of FFA, in turn related to insulin resistance and visceral type of adipose tissue distribution. A rise in plasma FFA levels induced by lipidheparin infusion, impaired GH responsiveness to Table 1 Biochemical data in ten obese subjects (before biliopancreatic diversion (BPD) and after BPD-induced weight normalisation), in ten anorexia nervosa (AN) controls and in ten normal weight controls e Between AN and pre-BPD; f Between AN and post-BPD. FFA free fatty acids; HDL chol HDL cholesterol; T prot total proteins. Table 2 IGF-I, IGFBP-3 plasma levels, IGF-I/IGFBP3 molar ratio, total body mass (TBM), lean body mass (LBM) and fat mass (FM) in ten subjects (before biliopancreatic diversion (pre-BPD) and after BPD (post-BPD)), in ten anorexia nervosa (AN) controls and in ten normal weight controls
Pre-BPD (n 10) 134.50 AE 18 A similar GH suppression by FFA was reported in rats. 19 Our data also show FFA plasma levels in obese pre-BPD subjects, signi®cantly higher than in normal weight ones. A direct role of insulin has been suggested by Rasmussen et al, 20 since weight loss, inducing a decrease of insulin secretion, restored a normal 24 h GH pro®le. Moreover, insulin is able to reduce GH release from rat pituitary, in vitro, suggesting an IGF-I-like effect. 21 According to this suggestion, basal insulin levels were found to be very high in pre-BPD patients ( Table 1) .
The reason for the paradoxical GH responses in obese subjects to GHRH after a meal is not known. Again, central and peripheral factors have been claimed to explain such a phenomenon.
Among central factors, b-endorphins could be involved, since a naloxone infusion blocks the postprandial GH increase. 16 A chronically decreased hypothalamic cholinergic tone, resulting in an increased SRIF tone, has also been hypothesised. 22 Among peripheral factors, metabolic fuels could directly in¯uence the hypothalamic balance between stimulating and inhibition factors for GH. GH is not suppressed by oral glucose in obesity, 18 but the further increase after a meal could indicate not only a lack of inhibition, but rather an altered hypothalamic sensitivity to metabolites. Maccario et al 23 observed that while pirenzepine, a direct cholinergic drug, abolished the GH response to GHRH and arginine, as in normal humans, obese subjects differed from the controls with respect to glucose action; the GHRH-and arginineinduced GH release were refractory to the inhibitory effect of glucose. The authors suggested a reduced glucose utilisation, due to hyperinsulinaemia, in brain areas, including somatostatinergic neurons, so that hyperglycaemia is not suf®cient to trigger SRIF release. Finally, gut hormone release could in¯uence GH secretion. Several hormones, including CCK and secretin, are released from intestinal endocrine cells in response to food intake; other hormones, such as enteroglucagon and glucagon-like peptide, may act through paracrine release of SRIF, which mediates inhibition of gastric acid secretion, modulation of insulin release and perhaps the inhibition of GHRH-GH-IGF axis. 24 The peripheral SRIF release could explain the blunting effect of a meal on GHRHinduced GH release observed in normal subjects, 6 while obese women have blunted somatostatin response in comparison to normal subjects. 25 Finally, the postprandial insulin increase could exert such an effect through its own receptors or IGF-I receptors. 26 The fasting hyposecretory state is reversed by weight loss obtained either by dieting 4 or surgical procedures. 3 Williams et al 3 showed that weight loss, obtained by surgical by-pass, induces a normalisation of the GH response to GHRH, when the subjects were tested in the fasting state. In agreement with this observation, our study also shows that BPD-induced weight loss is accompanied by a restoration of a normal GH response to GHRH.
Moreover, a new ®nding of this study is that the paradoxical GH response after a meal was still persistent and is further increased by a meal, after the surgically-induced body weight normalisation. This alteration seems to be therefore independent of BW. The decrease of FFA levels could trigger a disinhibition of postprandial GH response. The role of IGF-I seems to be unimportant in our experiments, since IGF-I and IGF-IaIGFBP-3 values were not modi®ed by BPD. The most signi®cant in¯uence seems to be exerted by insulin, according to our data (see multivariate analysis).
The metabolic effect of BPD and its re¯ection on GH is strongly reinforced by the comparison with AN. In a previous study, we have reported that the opposite extremes of nutritional state, obesity and AN, share GH secretion abnormalities. 6, 27 Alterations of GH secretion in AN are demonstrated by several data obtained both in animal and in human models. In a group of food restricted sheep, plasma GH levels increased, due to an increase in pulse amplitude without affecting GH pulse frequency and no variation was observed in GHRH. On the contrary, portal concentrations of SRIF were half those of sheep on a normal diet. 28 In food-deprived rats, the GH response to GHRH is signi®cantly greater than in SRIF-infused normally-fed rats, suggesting that SRIF concentrations may decrease during food deprivation. 29 Previous studies, in AN patients, have reported a paradoxical GHRH-induced GH increase after meals 6, 27, 30 and during hyperglycaemia. 31 Opioid involvement andaor altered hypothalamic cholinergic tone, resulting in a decreased SRIF tone, has been hypothesised to explain the augmented GH response in AN patients after meals. 27, 30, 32 The persistence of the paradoxical GH postprandial response to GHRH in post-BPD subjects, which does not signi®cantly differ from that observed in AN patients, suggests the role of metabolic fuels in the regulation of SRIF secretion. BPD signi®cantly reduced insulin, triglycerides, FFA levels and FM. This observation could reinforce the hypothesis that the restoration of GH response to exogenous GHRH is, in some way, modulated by endogenous insulin. A facilitating role of reduced FFA, observed both in post-PBD subjects and in AN, is also probably involved.
Conclusion
Finally, the pattern of gut hormone response to a meal is not entirely similar in these two different models: AN is characterized by a decrease in CCK response 33 and augmented somatostatin secretion 26 after a meal. BPD induces elevated plasma CCK concentrations and increases the release of enteroglucagon, which is a factor controlling somatostatin secretion.
10,12,24
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Further studies can clarify the complex mechanisms of endocrine and metabolic sequences of BPD. However, taken together, our data strengthen the metabolic hypothesis: surgical procedure makes obese patients similar to anorexics, in the relationships between metabolic fuels, food ingestion and GH secretion. The persistence of the GH postprandial response to GHRH in post-BPD subjects, suggests the role of metabolic fuels in the regulation of SRIF secretion and an in¯uence on central regulation of GH secretion in such patients.
